This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Unspecified nonorganic psychosis상세불명의 비기질성 정신병 (상세불명비기질성정신병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: F29 (Unspecified nonorganic psychosis) | Special Copayment Reduction: V161 (severe intractable disease, copayment reduction for 5 years after registration)
B. SynonymsPsychosis NOS, Unspecified nonorganic psychotic disorder
C. Adult onsetLikelihood of first onset in adulthood: high — a provisional code used when psychotic symptoms are present but a specific diagnostic classification is not possible or information is insufficient; applicable at all adult ages and most frequently used in emergency admissions for first-episode psychosis.
1. HistoryEstablished in ICD-10 as the broadest residual category for nonorganic psychoses that cannot be classified under any of the F20-F28 categories; used temporarily in emergency, first-episode, and information-poor situations; should not be kept as a long-term code, and reclassification is needed once sufficient clinical information has been obtained.
2. CausesA state in which the underlying cause of psychotic symptoms is unclear or not sufficiently investigated at the time of evaluation; applies when differentiation, from organic causes (brain disease, drugs, metabolic abnormalities) to nonorganic causes (schizophrenia, mood psychosis, brief reactive psychosis), is incomplete.
3. GeneticsF29 is a provisional code before diagnosis is confirmed, so there are no specific genetic studies; the genetic risk of the corresponding disease applies according to the final confirmed diagnosis; the content of genetic counseling differs depending on which category it is assigned to: schizophrenia spectrum, mood disorder, or brief reactive psychosis.
4. General epidemiologyThere are no independent epidemiologic data for the F29 code itself; in practice, many patients with first-episode psychosis are initially coded as F29 and reclassified after follow-up; in first-episode psychosis (FEP) cohorts, about 70-80% are converted to a specific diagnostic code within 6-12 months.
5. PathophysiologyThe pathophysiology is unclear at the time the F29 code is used; dopamine system abnormalities and abnormal serotonin-glutamate interactions are commonly understood to be involved in the development of psychotic symptoms; after the final diagnosis is confirmed, the pathophysiology of the corresponding disease applies.
6. SymptomsPsychotic symptoms such as auditory hallucinations, visual hallucinations, delusions, and disorganized thinking and behavior are present, but it is unclear whether specific diagnostic criteria are met; includes cases where acute-phase symptoms are so severe that an adequate psychiatric interview is not possible; cases where the duration and pattern of symptoms are not yet established.
7. SignsThe presence of psychotic symptoms (hallucinations, delusions, disorganized thinking) is confirmed on psychiatric interview, but evaluation of whether the F20-F28 criteria are met is not yet complete; neurological signs and exclusion of organic causes may be incomplete; recording the mental status examination (MSE) results is essential.
8. ScreeningStart systematic differential diagnostic testing immediately upon using F29; brain MRI/CT, EEG, autoimmune encephalitis panel (anti-NMDAR, anti-LGI1, anti-CASPR2), blood and urine tests (metabolic, endocrine, toxic), CSF analysis; collect past history and family history; record symptoms with PANSS or BPRS.
9. DiagnosisF29 is a provisional code; after exclusion of organic causes is complete → systematic review of the F20-F28 criteria → reclassify as quickly as possible to the diagnostic code that is met; target timing for reclassification: 3-6 months after outpatient stabilization, within 12 months at the latest; if use continues, the basis for reassessment must be documented.
10. TreatmentPrioritize control of acute-phase symptoms with second-generation antipsychotics (olanzapine, risperidone, aripiprazole, etc.); start early treatment if clinically necessary even when the diagnosis is unclear; decide on adding mood stabilizers or antidepressants according to the final confirmed diagnosis; combine with mental health education and supportive treatment.
11. PrognosisPrognosis is determined by the final confirmed diagnosis rather than by F29 itself; prognosis is good when reclassified as brief reactive psychosis (F23); attention to the long-term course is needed when reclassified as schizophrenia (F20); management is needed so that delay in confirming the diagnosis does not itself lead to delay in treatment.
12. PreventionEarly detection and treatment of first-episode psychosis (shortening DUP); monitoring of the high-risk group (CHR-P); prevention of substance abuse; relapse prevention with maintenance antipsychotic treatment; after the diagnosis is confirmed, switch to disease-specific prevention strategies.
13. ReferencesFusar-Poli P, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013 … and 9 other papers

1. History

Unspecified nonorganic psychosis (F29) is the last residual code in the ICD-10 classification system for a state in which psychotic symptoms are present but cannot be classified under any specific category of F20-F28, or in which sufficient information for classification cannot be obtained. It functions as the broadest and most inclusive NOS (Not Otherwise Specified) category in the entire F2x nonorganic psychosis series of ICD-10.

Historically, the use of 'NOS' or 'unspecified' codes in psychiatry arose from the recognition that diagnostic classification systems cannot encompass the full diversity of clinical reality. Since Pinel and Esquirol attempted to classify mental illnesses systematically in the early 19th century, cases that do not fit existing categories have persisted in clinical practice. Even after the introduction of Kraepelin's dichotomy (dementia praecox versus manic-depressive illness), cases at this boundary raised the need for a separate classification.

In the DSM classification system, the corresponding code is 'Unspecified Schizophrenia Spectrum and Other Psychotic Disorder'. The abandonment of the term 'NOS' in DSM-5 and its division into 'Other Specified' and 'Unspecified' was intended to improve clinical transparency. 'Other Specified' is used when the clinician specifies the reason the diagnostic criteria are not met, and 'Unspecified' is used when specifying the reason is difficult or impossible.

In ICD-10, F29 is used in actual practice mainly in three situations. First, during emergency admission and acute-phase evaluation, when psychotic symptoms have been confirmed but collection of the information needed to confirm the diagnosis is not yet complete. Second, when transfer (referral) records are insufficient, that is, when care begins without sufficient diagnostic information provided by the referring institution. Third, when the symptom pattern is atypical and does not clearly fit any diagnostic category, a state that requires long-term follow-up.

In ICD-11 (2022), a similar residual category was retained, but a system of additional clinical specifiers was strengthened to improve diagnostic accuracy. In clinical practice, continuous reassessment and reclassification efforts are emphasized so that F29 is not kept as a long-term code. In the Korean National Health Insurance claims system, F29 can be registered for Special Copayment Reduction V161, and re-registration should be reviewed if the diagnosis is changed later.


2. Causes

Unspecified nonorganic psychosis (F29) by definition reflects a state in which the cause is still unclear or has not been sufficiently evaluated. Therefore, using the F29 code means that work to identify the cause is under way, and it is a clinical duty to establish the underlying cause and diagnosis as soon as possible.

Differentiating organic from nonorganic causes: When F29 is applied, the top priority is exclusion of organic causes. Neurological causes include brain tumor (especially limbic system and temporal lobe), temporal lobe epilepsy, autoimmune encephalitis (anti-NMDAR, anti-LGI1, anti-CASPR2, and anti-GABA-B antibodies), cerebrovascular disease, and early stages of neurodegenerative disease. Metabolic and endocrine causes include hyperthyroidism, Cushing syndrome, hyperparathyroidism, hypoglycemia, and hyperammonemia. Drug-induced causes include steroids, interferon, antiparkinsonian agents, and some anticancer drugs, and substance-related causes include stimulants (amphetamine, methamphetamine), cannabis, synthetic cannabinoids, hallucinogens (LSD, psilocybin), and alcohol withdrawal.

Etiologic heterogeneity of the nonorganic psychosis spectrum: Even when classified as F29 after exclusion of organic causes, the potential causes are heterogeneous. Some may be an early stage (prodrome) of schizophrenia, and some may develop into a psychotic episode in a mood disorder, brief reactive psychosis, the early stage of delusional disorder, or schizoaffective disorder. Common neurobiological mechanisms considered include overactivation of dopamine D2 receptors, abnormal serotonin-dopamine interaction, and reduced function of glutamate NMDA receptors.

Period of unknown cause in first-episode psychosis (FEP): During the period in which the F29 code is used in patients with first-episode psychosis, it is common for several biological and psychosocial causal factors to act simultaneously. Neurodevelopmental vulnerability (perinatal complications, neurodevelopmental abnormalities), sensitization of the dopamine system, increased stress reactivity (kindling effect), and sociocultural factors (immigration, urban residence, traumatic experiences) are involved in combination. The longer the duration of untreated psychosis (DUP), the worse the prognosis, so treatment must start at the same time as identification of the cause.

Importance of searching for biological markers: The period in which the F29 code is used is an opportunity to search for biological markers to identify the cause. Systematic collection of structural abnormalities on brain MRI (decreased hippocampal volume, lateral ventricular enlargement), abnormal waveforms on EEG (especially temporal lobe epileptic discharges), immunologic indicators (autoimmune antibodies), endocrine indicators (cortisol, thyroid hormones), and pharmacokinetic indicators (blood drug concentration) contributes to confirming the diagnosis.


3. Genetics

Unspecified nonorganic psychosis (F29) is a provisional code before diagnosis is confirmed, so there have been no cases that were the subject of specific genetic studies. Therefore, no independent research data exist on the genetics of F29 itself. However, depending on which of F20-F28 patients classified as F29 are later reclassified into, the genetic characteristics of that diagnosis apply.

Shared genetic vulnerability of the psychosis spectrum: To understand the genetic background of first-episode psychosis patients classified as F29, the shared genetic vulnerability across the entire psychosis spectrum must be considered. According to large-scale GWAS (genome-wide association study) studies, schizophrenia, bipolar disorder, and major depressive disorder share a substantial genetic architecture. The heritability of schizophrenia is estimated at about 80% and that of bipolar disorder at about 60-80%, and the genetic correlation (rg) between the two diseases is reported to be about 0.6-0.7.

Copy number variants (CNV) and first-episode psychosis: Copy number variants (CNV) found at high frequency in first-episode psychosis patients include 22q11.2 deletion syndrome (about 25- to 30-fold increase in risk of developing schizophrenia), 15q11.2 deletion, 1q21.1 duplication, and 16p11.2 deletion and duplication. Considering screening for high-risk CNVs during the period in which the F29 code is used may help set the diagnostic direction. In particular, 22q11.2 deletion syndrome is clinically recognizable because it accompanies congenital heart malformation, cleft palate, and characteristic facial features.

Potential clinical use of polygenic risk scores (PRS): Recent studies suggest that the schizophrenia polygenic risk score (PRS) may be used to predict the risk of conversion to schizophrenia in first-episode psychosis patients. First-episode psychosis patients with a high PRS are likely to be reclassified as schizophrenia, and when the PRS is low and mood symptoms accompany, they are likely to be reclassified as mood psychosis. However, the evidence for clinical application is still at the research stage, and it is not recommended as standard clinical practice.

A practical approach to genetic counseling: When the patient's family asks about genetic risk during the period in which the F29 code is used, it should be explained that exact heritability figures are difficult to give because the final diagnosis has not been confirmed. However, general information can be provided that, in general, the risk of onset is higher than in the general population when there is a family history of psychosis spectrum disorders. After the diagnosis is confirmed, it is appropriate to link to disease-specific genetic counseling.


4. General epidemiology

Virtually no independent epidemiologic data exist for unspecified nonorganic psychosis (F29). Because F29 is a provisional code rather than a final diagnosis, it is not analyzed as a separate diagnostic category in epidemiologic studies. However, the epidemiology of first-episode psychosis (FEP) cohorts, the situation in which F29 is most frequently used, is indirectly relevant.

Epidemiology of first-episode psychosis: The annual incidence of first-episode psychosis is reported to be about 15-35 per 100,000 population. The mean age at onset is about 18-25 years in men and about 25-35 years in women, about 5-10 years later in women. The male-to-female ratio is overall similar, but male predominance is reported in the early-onset group (under 18 years) and female predominance in the late-onset group (45 years and older). The incidence is higher among urban residents, immigrants, and socioeconomically vulnerable groups.

Frequency of F29 use in first-episode psychosis: A considerable proportion of acute psychiatric inpatients admitted with first-episode psychosis are initially coded as F29 or F23. According to studies, about 20-40% of first-episode psychosis patients are provisionally classified as F29 or F23 at the time of admission. After 6-12 months of follow-up, about 70-80% are reclassified to a specific diagnostic code. The most common reclassification result is schizophrenia (F20) (about 40-50%), followed by mood psychosis (associated with F25, F30, F31), brief reactive psychosis (F23), and others.

Duration of untreated psychosis (DUP) and epidemiologic significance: Minimizing the period in which the F29 code is used provisionally is also part of the strategy to shorten DUP. Worldwide, the mean DUP of first-episode psychosis patients is very long, at about 12-24 months, and a similar trend is reported in Korea. Shortening DUP through expansion of early intervention programs (Early Intervention in Psychosis, EIP) and minimizing the period of F29 use is the international recommended direction.


5. Pathophysiology

The pathophysiology is still unclear at the time the unspecified nonorganic psychosis (F29) code is used. However, the neurobiological mechanisms of the psychotic symptoms themselves involve mechanisms common to F20-F28, so understanding them is clinically useful.

Dopamine hyperactivity hypothesis: As the core neurobiological mechanism of psychotic symptoms, overactivation of the mesolimbic dopamine pathway is the best established. According to Kapur's aberrant salience theory, dopamine overactivation assigns inappropriate salience to unrelated stimuli, forming delusions and hallucinations. This theory explains the mechanism by which antipsychotics relieve symptoms through D2 blockade.

Reduced glutamate NMDA receptor function: The glutamate hypothesis developed from the fact that PCP (phencyclidine) and ketamine block NMDA receptors and induce schizophrenia-like symptoms. Reduced NMDA receptor function causes increased cortical excitability and dopamine overactivation through decreased activity of inhibitory GABAergic interneurons. This mechanism explains not only positive symptoms but also negative symptoms and cognitive decline.

Serotonin-dopamine interaction: That second-generation antipsychotics have both D2 blockade and 5-HT2A blockade reflects the clinical use of the serotonin-dopamine interaction. 5-HT2A receptor blockade increases dopamine release in the prefrontal cortex, contributing to improved cognitive function and fewer extrapyramidal side effects. In first-episode psychosis patients, the 5-HT2A/D2 ratio is being studied as a biomarker that predicts the direction of the final diagnosis.

Neuroinflammation and HPA axis abnormalities: Studies are accumulating showing that inflammatory markers such as serum interleukin-6 (IL-6) and C-reactive protein (CRP) are elevated in first-episode psychosis patients. Chronic cortisol elevation due to overactivation of the HPA (hypothalamic-pituitary-adrenal) axis causes hippocampal neuronal damage and decline in memory and cognitive function. These neuroinflammatory and stress-response abnormalities are being studied as predictors of conversion from F29 to F20.


6. Symptoms

The symptoms of unspecified nonorganic psychosis (F29) by definition include psychotic symptoms observed when they cannot be clearly assigned to a specific diagnostic category or when the information needed for diagnosis is insufficient.

Positive symptoms: Auditory hallucinations are the most common symptom, and their content varies: self-critical, commanding, screaming, or conversing voices. Visual hallucinations are less common than auditory hallucinations and strongly suggest organic causes (autoimmune encephalitis, dementia with Lewy bodies, drugs), so careful differentiation is needed. Delusions can appear in various forms, including persecutory, referential, grandiose, and somatic delusions. Disorganized thinking (loosening of associations, flight of ideas, derailment) and disorganized behavior (purposeless behavior, catatonic behavior) are also included.

Negative symptoms: Alogia, avolition, anhedonia, social withdrawal, and blunted affect may appear. If negative symptoms are prominent at the F29 stage, the possibility of conversion to schizophrenia (F20) should be strongly considered. Conversely, if negative symptoms are mild and mood symptoms are in the foreground, the possibility of mood psychosis (F25, F30 series) is considered.

Possible accompanying mood symptoms: When mood symptoms (depression, mania, mixed) accompany at the F29 stage, reclassification toward schizoaffective disorder (F25) or psychosis in a mood episode is considered. It is important to determine through follow-up whether mood symptoms occupy a substantial part of the overall course of psychotic symptoms and whether psychotic symptoms occur independently of mood episodes.

Cognitive dysfunction: In many first-episode psychosis patients, neurocognitive decline in the domains of working memory, processing speed, executive function, and verbal memory is identified. This is a useful indicator for predicting conversion to F20. Neurocognitive assessment (MATRICS, COGSTATE, etc.) performed at the time of first episode can be used as baseline data.


7. Signs

In unspecified nonorganic psychosis (F29), the signs identified by clinical interview and physical examination play a key role in setting the subsequent diagnostic direction. It is a clinical duty to systematically record every item of the mental status examination (MSE).

Signs on mental status examination (MSE): In appearance, decreased self-care and irrational dress may be observed. Behavior includes actions that appear to respond to auditory hallucinations (looking to the side or talking to oneself), psychomotor retardation or agitation, and catatonic signs (waxy flexibility, echopraxia, echolalia). In speech, loosening of associations, poverty of speech, and neologisms may be observed. In thought content, the nature and degree of systematization of delusions and thoughts of harming oneself or others are assessed. Orientation and memory function must be assessed to exclude organic causes.

Neurological signs and signs suggesting organic causes: Neurological soft signs, namely incoordination, mirror movements, and sensory integration abnormalities, are common in the schizophrenia spectrum. In contrast, postictal confusion, autonomic instability (tachycardia, sweating, fever), involuntary movements (chorea, myoclonus), fluctuating level of consciousness, and abrupt changes in cognitive function strongly suggest organic causes, so immediate neurological evaluation is needed.

Clinical importance of catatonic signs: Catatonia can be observed not infrequently in F29 patients, and differential diagnosis is important. Catatonia can appear in schizophrenia, mood disorders, autoimmune encephalitis, metabolic diseases, and drug side effects alike. It should be assessed systematically with tools such as the BUSH-FRANCIS Catatonia Rating Scale (BFCRS), and malignant catatonia (hyperthermia, autonomic instability) must be checked for immediately.

Necessity of assessing risk of harm to self and others: Assessment of the risk of harm to self and others is essential even at the F29 stage. First-episode psychosis patients are at risk of self-harm due to command hallucinations and impulsive behavior due to delusions, and suicide risk is high when depressive symptoms accompany. Use standardized suicide risk assessment tools (C-SSRS, etc.), and ensuring safety in the inpatient setting is the priority.


8. Screening

The most important clinical duty at the time the unspecified nonorganic psychosis (F29) code is used is to begin systematic differential diagnostic testing immediately. This is essential so as not to miss treatable organic causes and to confirm the diagnosis promptly.

Essential blood tests: Complete blood count (CBC), electrolytes, renal function (BUN/Cr), liver function (AST/ALT/GGT), blood glucose, thyroid function (TSH, fT4), vitamin B12, folate, vitamin D, serum iron, calcium, phosphorus, magnesium. Infection and inflammation markers: CRP, ESR, blood culture (if infection is suspected). Endocrine: cortisol (if adrenal insufficiency is suspected), sex hormones (if needed). Toxicology screening: urine and blood drug screening (cannabis, stimulants, opiates, benzodiazepines, cocaine).

Autoimmune encephalitis panel: Autoimmune encephalitis is a treatable organic cause, so it must be considered in first-episode psychosis. Serum and CSF: anti-NMDAR antibody, anti-LGI1 antibody, anti-CASPR2 antibody, anti-GABA-B antibody, anti-AMPA antibody. In addition, antithyroid antibodies (Hashimoto encephalopathy) and ANCA (vasculitis-related encephalitis) are also tested according to clinical suspicion. In particular, the possibility of anti-NMDAR antibody encephalitis should be highly considered in first-episode psychosis in women in their 20s to 40s (associated with ovarian teratoma).

Neuroimaging: Brain MRI (with contrast): confirm limbic encephalitis pattern (increased T2 FLAIR signal in hippocampus and amygdala), brain tumor, demyelinating lesions, stroke, cortical dysplasia. Brain CT: as an alternative when MRI is not possible, screening for hemorrhage and space-occupying lesions. Brain SPECT or PET: if needed, evaluation of metabolic abnormalities and epileptic foci.

Electroencephalography (EEG): Temporal lobe epilepsy can cause psychosis-like symptoms such as hallucinations and delusions, so EEG is routinely recommended in first-episode psychosis patients. Sleep EEG or prolonged EEG monitoring is needed in some cases.

Neurocognitive assessment and psychiatric scales: Establish symptom baseline with PANSS (Positive and Negative Syndrome Scale) or BPRS. Screen cognitive function with the Mini-Mental State Examination (MMSE) or MoCA. Record function and severity with the GAF (Global Assessment of Functioning) and CGI-S (Clinical Global Impression-Severity).


9. Diagnosis

Unspecified nonorganic psychosis (F29) is a provisional code rather than a final diagnosis, and the aim of the diagnostic procedure is to convert the F29 code into a more specific diagnosis. The systematic diagnostic procedure for this proceeds in stages.

Step 1: Exclusion of organic causes: Systematically exclude organic causes through the blood tests, autoimmune panel, brain MRI, EEG, and urine drug testing described above. If an organic cause is identified, code with the corresponding organic cause code (F00-F09) instead of F29. If autoimmune encephalitis is confirmed, begin immunotherapy (IVIG, steroids, rituximab) immediately.

Step 2: Systematic review of ICD-10 F20-F28 criteria: After excluding organic causes, review the nonorganic psychosis categories in order. Schizophrenia (F20): first-rank symptoms (specific auditory hallucinations, thought insertion, broadcasting, and withdrawal, experiences of bodily passivity, delusional perception), negative symptoms, duration (1 month or more). Schizotypal disorder (F21): subthreshold symptoms, eccentric behavior. Persistent delusional disorder (F22): non-bizarre systematized delusions, no or mild hallucinations. Acute and transient psychotic disorder (F23): rapid onset within 2 weeks, precipitating stress, rapid full remission. Schizoaffective disorder (F25): both psychotic symptoms and a mood episode satisfied simultaneously. Other nonorganic psychotic disorders (F28): none of the above categories met, form of chronic hallucinatory psychosis.

Step 3: Timing of reclassification and conditions for continued use of F29: If F29 was used at first-episode admission, attempt reclassification before discharge or, at the latest, within 3 months after the first outpatient visit. If reclassification is not possible because of lack of information, continued use of F29 is allowed, but the reason reclassification is not possible and the future reassessment plan must be stated in the medical record. Goal: reclassification of 70% or more within 6 months and 90% or more within 12 months.

Comparison with DSM-5: The corresponding codes in DSM-5 are 'Other Specified Schizophrenia Spectrum and Other Psychotic Disorder (F28)' and 'Unspecified Schizophrenia Spectrum and Other Psychotic Disorder (F29)'. In DSM-5, 'Other Specified' is used when the clinician can record the reason the diagnostic criteria are not met, and 'Unspecified' when recording is difficult. In Korean National Health Insurance claims, ICD-10 codes take precedence.


10. Treatment

Treatment at the unspecified nonorganic psychosis (F29) stage aims at rapid control of psychotic symptoms and functional recovery despite diagnostic uncertainty. The principle of 'treatment after the diagnosis is confirmed' does not apply to F29, and starting early treatment according to clinical need is recommended.

Acute-phase antipsychotic treatment: First-episode psychosis patients are highly responsive to antipsychotics, so start at a low dose. Second-generation antipsychotics are preferred in first-episode patients because they have fewer extrapyramidal side effects. Olanzapine (5-10 mg/day), risperidone (1-3 mg/day), aripiprazole (10-15 mg/day), quetiapine (150-400 mg/day), and others are used. In acute agitation, intramuscular formulations (olanzapine IM, aripiprazole IM, haloperidol IM) can be used. At the stage of unclear diagnosis, be cautious about adding mood stabilizers and antidepressants, and consider adding them once mood symptoms become clear.

Concurrent treatment of organic causes: If autoimmune encephalitis is identified during the period in which the F29 code is used, start immunotherapy (high-dose steroids, IVIG) immediately in parallel with antipsychotics. If drug-induced psychosis is identified, discontinue the causative drug and observe the course. If thyroid dysfunction is identified, start the corresponding treatment.

Psychosocial intervention: Early intensive intervention in first-episode psychosis is important for improving prognosis. Supportive psychotherapy improves understanding of the illness and treatment adherence. Cognitive behavioral therapy (CBT-p) is effective in reducing the distress of delusions and auditory hallucinations. Family psychoeducation contributes to relapse prevention and reduction of family burden. Vocational rehabilitation and social skills training support functional recovery.

Adjusting treatment according to diagnostic change: When reclassified from F29 to schizophrenia (F20), establish long-term maintenance antipsychotic therapy and a relapse prevention plan. When reclassified as F25 (schizoaffective disorder), add a mood stabilizer or antidepressant. When reclassified as F23 (brief reactive psychosis), consider stepwise dose reduction and discontinuation of medication after full remission. A review of the Special Copayment Reduction code may also be needed at the same time as reclassification.


11. Prognosis

The prognosis of unspecified nonorganic psychosis (F29) itself does not provide a meaningful indicator. The actual prognosis is determined by the subsequent confirmed diagnosis. However, prognostic predictors identified at the first-episode psychosis stage are useful for predicting the subsequent course.

Predictors of good prognosis: Acute onset (within 2 weeks), presence of a clear precipitating stress, good premorbid social and occupational functioning, prominent accompanying mood symptoms, short DUP, high insight, presence of a social support system, rapid symptom response to first treatment (50% or more symptom reduction within 2-4 weeks), and mildness of negative symptoms and cognitive decline are associated with good prognosis.

Predictors of poor prognosis: Insidious onset, long DUP, poor premorbid functioning, strong negative symptoms and cognitive decline, family history of schizophrenia, insufficient response to initial treatment, comorbid substance abuse, male sex (in early onset), social isolation, and poor adherence are associated with poor prognosis.

Long-term prognosis data from first-episode psychosis cohorts: According to long-term follow-up studies, about 14-22% of first-episode psychosis patients maintain full remission after a single episode. About 40-50% experience repeated relapse and remission, and about 30-35% show a chronic course. The first 2 years after starting treatment are the decisive period for functional recovery, and intensive intervention during this period has the greatest effect on long-term prognosis.

Diagnostic conversion and change in prognosis: When reclassified from F29 to F23 (brief reactive psychosis), about 50-60% show a good prognosis, maintaining full remission without further episodes. When reclassified as F20 (schizophrenia), the functional prognosis is relatively poor and continuous maintenance treatment is needed. When reclassified as F25 (schizoaffective disorder), the prognosis is intermediate, and control of mood episodes is important for the overall prognosis.


12. Prevention

The preventive approach at the unspecified nonorganic psychosis (F29) stage proceeds in two directions. One is to prevent worsening and relapse of symptoms, and the other is to secure the optimal opportunity for treatment before the diagnosis is confirmed. After the diagnosis is confirmed, the prevention strategy for the corresponding disease applies.

Shortening the duration of untreated psychosis (DUP): Shortening DUP in first-episode psychosis is an important prevention strategy for improving long-term prognosis. A DUP of 1 year or more is associated with cognitive decline, decline in social functioning, and reduced treatment response. DUP can be shortened through community mental health education, strengthening of early referral systems among general practitioners, and school and workplace mental health programs. Use and expansion of Korea's national mental health screening program is recommended.

Monitoring of the clinical high-risk group (CHR-P): Early identification and monitoring of individuals in a Clinical High Risk for Psychosis (CHR-P) state can prevent or delay the onset of psychosis. CHR-P criteria: attenuated psychotic symptoms (ARMS), brief limited intermittent psychotic symptoms (BLIPS), first-degree relative with a psychosis spectrum disorder + functional decline. Interventions studied in the CHR-P state include cognitive behavioral therapy, omega-3 fatty acid supplementation, and low-dose antipsychotics (in some studies).

Prevention of substance abuse: Substance abuse such as cannabis and stimulants is a major risk factor for onset and relapse of psychosis. Assessment of and intervention for substance abuse should begin from the F29 stage. When a comorbid substance use disorder is present, integrated treatment through a dual diagnosis program is needed.

Relapse prevention through maintenance antipsychotic treatment: Maintenance treatment for at least 1-2 years after stabilization of acute-phase symptoms is recommended. Early discontinuation of antipsychotics after the first episode sharply increases the relapse rate. Consider long-acting injectables (LAI) to improve adherence. After the final diagnosis is confirmed, specify the maintenance treatment strategy according to the relapse prevention guidelines for the corresponding disease.

Strengthening the social support system: Building a comprehensive social support system from the time of first episode, including family psychoeducation, case management, community linkage, vocational rehabilitation, and housing support, contributes to relapse prevention and functional recovery. Integrated management within the early intervention program (EIP) framework yields optimal results.


13. References

  1. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70(1):107–120.
  2. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. 2008;7(3):148–156.
  3. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13–23.
  4. Murray RM, Bhavsar V, Tripoli G, Howes O. 30 Years on: how the neurodevelopmental hypothesis of schizophrenia morphed into the developmental risk factor model of psychosis. Schizophr Bull. 2017;43(6):1190–1196.
  5. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.
  6. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73(4):414–419.
  7. Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia. JAMA Psychiatry. 2017;74(7):675–684.
  8. Nordentoft M, Wahlbeck K, Hällgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013;8(1):e55176.
  9. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071.
  10. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Geneva: WHO; 1992. Chapter V: Mental and Behavioural Disorders (F00–F99).